Compare D Wave Quantum Inc (QBTS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D Wave Quantum Inc vs Sanofi SA — how do they compare? D Wave Quantum Inc trades at $17.35 (market cap $6.59B), while Sanofi SA trades at $43.89 (market cap $104.85B). The key difference: Sanofi SA is far larger — about 15.9× D Wave Quantum Inc's market cap, and Sanofi SA pays a 5.53% dividend while D Wave Quantum Inc pays none. Which is the better fit depends on your goals.
| QBTS | SNY | |
|---|---|---|
Market Cap | $6.59B | $104.85B |
Sector | Technology | Health |
52-Week High | $44.78 | $52.34 |
52-Week Low | $12.98 | $41.33 |
Enterprise Value | $6.05B | $121.38B |
Dividend Yield | — | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QBTS trades at $16.73, showing no change in the last 24 hours. The stock is technically bearish with key support at $16 and resistance at $17. Fundamentally, the company reported a net loss of $355.06 million on $24.59 million revenue in 2025, with a negative net income margin of -2,957.23%. Recent news highlights D-Wave's dual-platform quantum computing approach and a recent transfer of its stock listing to Nasdaq (Business Wire, July 14, 2026).
Despite unanimous analyst buy ratings and a $39.86 consensus price target implying significant upside, QBTS faces substantial execution risks. High cash burn, negative profitability, and intense competition in the emerging quantum computing sector present challenges. The stock's appeal hinges on future revenue growth materializing from current commercial partnerships and technological advancements.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
